需要胰岛素治疗与不需要胰岛素治疗的糖尿病对心房颤动患者血栓栓塞风险的影响:PREFER in AF 研究
基于前瞻性、真实世界、多中心 PREFER in AF 注册研究,纳入 5717 例心房颤动患者,其中 1288 例合并糖尿病(22.4% 使用胰岛素)。随访 1 年,使用胰岛素的糖尿病患者卒中/系统性栓塞发生率显著高于无糖尿病患者(5.2% vs 1.9%,HR 2.89)及未使用胰岛素的糖尿病患者(5.2% vs 1.8%,HR 2.96),而未使用胰岛素的糖尿病患者与无糖尿病患者风险相似(HR 0.97)。
要点
- 使用胰岛素的糖尿病患者 1 年卒中/系统性栓塞风险显著高于无糖尿病患者(5.2% vs 1.9%,HR 2.89)。
- 使用胰岛素的糖尿病患者风险显著高于未使用胰岛素的糖尿病患者(5.2% vs 1.8%,HR 2.96)。
- 未使用胰岛素的糖尿病患者与无糖尿病患者卒中/栓塞风险相似(HR 0.97,95%CI 0.58–1.61,p=0.90)。
核心结论
- 在抗凝治疗的心房颤动患者队列中,仅合并不需要胰岛素治疗的糖尿病并不意味血栓栓塞风险增加;需要胰岛素治疗的糖尿病贡献了心房颤动血栓栓塞风险总体增加的绝大部分甚至全部。
研究设计与样本
- 基于前瞻性、真实世界、多中心 PREFER in AF(欧洲血栓栓塞事件预防-欧洲心房颤动注册研究)的个体患者数据,比较不同糖尿病状态患者 1 年卒中/系统性栓塞发生率。
- 总体人群 5717 例,其中 1288 例合并糖尿病,22.4% 使用胰岛素。
主要发现
- 使用胰岛素的糖尿病患者 1 年卒中/系统性栓塞发生率 5.2%,无糖尿病患者 1.9%(HR 2.89,95%CI 1.67–5.02,p=0.0002)。
- 使用胰岛素的糖尿病患者 1 年卒中/系统性栓塞发生率 5.2%,未使用胰岛素的糖尿病患者 1.8%(HR 2.96,95%CI 1.49–5.87,p=0.0019)。
- 未使用胰岛素的糖尿病患者与无糖尿病患者卒中/栓塞发生率相似(HR 0.97,95%CI 0.58–1.61,p=0.90)。
- 需要胰岛素治疗的糖尿病的选择性预测作用独立于包括糖尿病病程在内的潜在混杂因素,并在包括接受抗凝治疗亚组在内的多个亚组中维持。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diabetes is a known risk predictor for thromboembolic events in patients with atrial fibrillation (AF), but no study has explored the prognostic weight of insulin in this setting. OBJECTIVES: This study evaluated the differential role of insulin versus no insulin therapy on thromboembolic risk in patients with diabetes and AF. METHODS: We accessed individual patient data from the prospective, real-world, multicenter, PREFER in AF (European Prevention of thromboembolic events-European Registry in Atrial Fibrillation). We compared the rates of stroke/systemic embolism at 1 year according to diabetes status (no diabetes, diabetes without insulin therapy, diabetes on insulin therapy). RESULTS: In an overall population of 5,717 patients, 1,288 had diabetes, 22.4% of whom were on insulin. For patients with diabetes who were on insulin, there was a significantly increased risk of stroke/systemic embolism at 1 year versus either no diabetes (5.2% vs. 1.9%; hazard ratio: 2.89; 95% confidence interval: 1.67 to 5.02; p = 0.0002) or diabetes without insulin treatment (5.2% vs. 1.8%; hazard ratio: 2.96; 95% confidence interval: 1.49 to 5.87; p = 0.0019). Notably, rates of stroke/embolism were similar in patients with diabetes not receiving insulin versus patients without diabetes (hazard ratio: 0.97; 95% confidence interval: 0.58 to 1.61; p = 0.90). The selective predictive role of insulin-requiring diabetes was independent of potential confounders, including diabetes duration, and was maintained in various subpopulations, including the subgroup receiving anticoagulant therapy. CONCLUSIONS: In this cohort of anticoagulated patients with AF, the sole presence of diabetes not requiring insulin did not imply an increased thromboembolic risk. Conversely, insulin-requiring diabetes contributed most, if not exclusively, to the overall increase of thromboembolic risk in AF.
引用
- Patti G, Lucerna M, Cavallari I, et al. Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation: PREFER in AF. J Am Coll Cardiol. 2017. PMID: 28126158. doi:10.1016/j.jacc.2016.10.069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。